Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Verweij, J.
Right arrow Articles by Lefebvre, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verweij, J.
Right arrow Articles by Lefebvre, J. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 7:867-869, 1996
© 1996 European Society for Medical Oncology

brief-report

Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck

J. Verweij1,, P. H. M de Mulder2, A. de Graeff3, J. B. Vermorken4, J. Wildier5, J. Kerger6, J. Schornagel7, F. Cognetti8, A. Kirkpatrick9, T. Sahmoud9 and J. L. Lefebvre10

1Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital Rotterdam
2University Hospital St. Radboud Nijmegen
3University Hospital Utrecht
4University Hospital ‘Vrije Universiteit’ Amsterdam, The Netherlands
5University Hospital St. Raphael Louvain
6Institute Jules Bordet Brussels, Belgium
7Netherlands Cancer Institute Amsterdam, The Netherlands
8Istituto Regina Elena Rome, Italy
9EORTC Data Center Brussels, Belgium
10Centre Oscar Lambret Lille, France

Correspondence to: Jaap Verweij, MD, PhD Department of Medical Oncology Rotterdam Cancer Institute Dr. Daniel den Hoed Kliniek Groene Hilledijk 301 3075 EA Rotterdam The Netherlands

BACKGROUND:: Based on activity in a case report, mitoxantrone was studied in a phase II study in adenoid cystic carcinoma.

PATIENTS AND METHODS:: Patients with symptomatic and/or rapidly progressive metastatic or recurrent adenoid cystic carcinoma were eligible for this study. They were treated with mitoxantrone given intravenously by bolus injection at a dose of 14 mg/m2, cycles repeated every 3 weeks.

RESULTS:: Thirty-six chemotherapy-naive patients entered on trial, 4 were ineligible. A median of 6 cycles per patient were given. Leucocytopenia (in 97% of patients) was the most important side effect and tended to be cumulative. Other side effects were mainly mild to moderate and consisted of nausea (62%), vomiting (29%), alopecia (53%) and mucositis (41%). Four of 32 patients had a partial response (12%; 95% CI 4%–29%) lasting 3–13 months, 22 patients (69%) had a stable disease.

CONCLUSIONS:: Mitoxantrone at this dose and schedule has modest activity in adenoid cystic carcinomas.

adenoid cystic carcinoma, mitoxantrone, phase II study


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
S. A. Laurie and L. Licitra
Systemic Therapy in the Palliative Management of Advanced Salivary Gland Cancers
J. Clin. Oncol., June 10, 2006; 24(17): 2673 - 2678.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. J. Hotte, E. W. Winquist, E. Lamont, M. MacKenzie, E. Vokes, E. X. Chen, S. Brown, G. R. Pond, A. Murgo, and L. L. Siu
Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study
J. Clin. Oncol., January 20, 2005; 23(3): 585 - 590.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.